516 related articles for article (PubMed ID: 28651157)
21. Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230).
Eastell R; Hannon RA; Cuzick J; Dowsett M; Clack G; Adams JE;
J Bone Miner Res; 2006 Aug; 21(8):1215-23. PubMed ID: 16869719
[TBL] [Abstract][Full Text] [Related]
22. Incidence and risk factors for non-alcoholic steatohepatitis in females treated with tamoxifen for breast cancer.
Akhondi-Meybodi M; Mortazavy-Zadah MR; Hashemian Z; Moaiedi M
Arab J Gastroenterol; 2011 Mar; 12(1):34-6. PubMed ID: 21429453
[TBL] [Abstract][Full Text] [Related]
23. A phase III randomized multicenter trial evaluating cognition in post-menopausal breast cancer patients receiving adjuvant hormonotherapy.
Le Rhun E; Delbeuck X; Lefeuvre-Plesse C; Kramar A; Skrobala E; Pasquier F; Bonneterre J
Breast Cancer Res Treat; 2015 Aug; 152(3):569-80. PubMed ID: 26160250
[TBL] [Abstract][Full Text] [Related]
24. Comparative assessment of lipid effects of endocrine therapy for breast cancer: implications for cardiovascular disease prevention in postmenopausal women.
Esteva FJ; Hortobagyi GN
Breast; 2006 Jun; 15(3):301-12. PubMed ID: 16230014
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
[TBL] [Abstract][Full Text] [Related]
26. Aromatase Inhibitors and Newly Developed Nonalcoholic Fatty Liver Disease in Postmenopausal Patients with Early Breast Cancer: A Propensity Score-Matched Cohort Study.
Lee JI; Yu JH; Anh SG; Lee HW; Jeong J; Lee KS
Oncologist; 2019 Aug; 24(8):e653-e661. PubMed ID: 30679317
[TBL] [Abstract][Full Text] [Related]
27. Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial.
Mouridsen H; Keshaviah A; Coates AS; Rabaglio M; Castiglione-Gertsch M; Sun Z; Thürlimann B; Mauriac L; Forbes JF; Paridaens R; Gelber RD; Colleoni M; Smith I; Price KN; Goldhirsch A
J Clin Oncol; 2007 Dec; 25(36):5715-22. PubMed ID: 17998546
[TBL] [Abstract][Full Text] [Related]
28. Letrozole or tamoxifen in early breast cancer.
Buzdar AU; Baum M; Cuzick J
N Engl J Med; 2006 Apr; 354(14):1528-30; author reply 1528-30. PubMed ID: 16598051
[No Abstract] [Full Text] [Related]
29. The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
Morandi P; Rouzier R; Altundag K; Buzdar AU; Theriault RL; Hortobagyi G
Cancer; 2004 Oct; 101(7):1482-9. PubMed ID: 15378476
[TBL] [Abstract][Full Text] [Related]
30. The optimal duration and selection of adjuvant endocrine therapy for breast cancer: how long is enough?
Smith IE; Yeo B; Schiavon G
Am Soc Clin Oncol Educ Book; 2014; ():e16-24. PubMed ID: 24857098
[TBL] [Abstract][Full Text] [Related]
31. Adjuvant aromatase inhibitor therapy in early breast cancer: what factors lead patients to discontinue treatment?
Moscetti L; Agnese Fabbri M; Sperduti I; Fabrizio N; Frittelli P; Massari A; Pompei L; D'Auria G; Pofi E; Ruggeri EM
Tumori; 2015; 101(5):469-73. PubMed ID: 26108239
[TBL] [Abstract][Full Text] [Related]
32. Extended adjuvant endocrine therapy in hormone-receptor positive breast cancer.
Strasser-Weippl K; Badovinac-Crnjevic T; Fan L; Goss PE
Breast; 2013 Aug; 22 Suppl 2():S171-5. PubMed ID: 24074782
[TBL] [Abstract][Full Text] [Related]
33. Switching trial of adjuvant tamoxifen with an aromatase inhibitor in postmenopausal patients with breast cancer.
Boccardo F
Clin Breast Cancer; 2004 Sep; 5 Suppl 1():S13-7. PubMed ID: 15347434
[TBL] [Abstract][Full Text] [Related]
34. Lipid concentrations in postmenopausal women on letrozole after 5 years of tamoxifen: an NCIC CTG MA.17 sub-study.
Wasan KM; Goss PE; Pritchard PH; Shepherd L; Tu D; Ingle JN
Breast Cancer Res Treat; 2012 Dec; 136(3):769-76. PubMed ID: 23089983
[TBL] [Abstract][Full Text] [Related]
35. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial.
; Buzdar A; Howell A; Cuzick J; Wale C; Distler W; Hoctin-Boes G; Houghton J; Locker GY; Nabholtz JM
Lancet Oncol; 2006 Aug; 7(8):633-43. PubMed ID: 16887480
[TBL] [Abstract][Full Text] [Related]
36. A prospective, randomized study on hepatotoxicity of anastrozole compared with tamoxifen in women with breast cancer.
Lin Y; Liu J; Zhang X; Li L; Hu R; Liu J; Deng Y; Chen D; Zhao Y; Sun S; Ma R; Zhao Y; Liu J; Zhang Y; Wang X; Li Y; He P; Li E; Xu Z; Wu Y; Tong Z; Wang X; Huang T; Liang Z; Wang S; Su F; Lu Y; Zhang H; Feng G; Wang S
Cancer Sci; 2014 Sep; 105(9):1182-8. PubMed ID: 24975596
[TBL] [Abstract][Full Text] [Related]
37. The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer.
Monnier AM
Expert Rev Anticancer Ther; 2007 May; 7(5):627-34. PubMed ID: 17492927
[TBL] [Abstract][Full Text] [Related]
38. Acute bilateral pulmonary emboli occurring while on adjuvant aromatase inhibitor therapy with anastrozole: Case report and review of the literature.
Lycette JL; Luoh SW; Beer TM; Deloughery TG
Breast Cancer Res Treat; 2006 Oct; 99(3):249-55. PubMed ID: 16752073
[TBL] [Abstract][Full Text] [Related]
39. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
Berry J
Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
[TBL] [Abstract][Full Text] [Related]
40. Changes in endocrine therapy: anastrozole and advanced breast cancer in postmenopausal women.
Nabholtz JM
Am J Hosp Palliat Care; 2004; 21(6):457-65. PubMed ID: 15612238
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
